Regenerative medicine needs better instructions for cells.
Syntax Bio expanded its Series A to $14.4M, bringing total funding past $25M, as
@john_craighead,
@RECdomain, Brad Merrill, and Niko Balanis advance Cellgorithm, a CRISPR-based platform that guides pluripotent stem cells through differentiation faster and more consistently.
The next cell therapy winners will not just grow cells. They will program development itself so regenerative medicine can move with greater speed, scale, and precision.